Current remedies for air leaks are largely mechanical. Synthetic polymer patches, biological grafts such as bovine pericardium and chemical pleurodesis with talc or bleomycin all aim to physically seal the defect or provoke inflammatory adhesions that glue the lung to the chest wall. These measures offer temporary relief but frequently aggravate the problem, triggering foreign body reactions, chronic inflammation and fibrosis that can produce recurrent leaks or pleural adhesions. What has been missing is a therapy that not only plugs the hole but regenerates the pleura’s native structure: a superficial mesothelial monolayer, submesothelial connective tissue and elastic fiber networks that together maintain pulmonary integrity through every breath.

Organoid technology offered the researchers a way forward. Organoids are self-organizing three-dimensional tissue mimics grown from stem cells that replicate the structural and functional complexity of their parent tissue. The approach has already delivered pancreatic islet organoids that restore glucose homeostasis in diabetic models, intestinal organoids that enhance epithelial regeneration after ischemia-reperfusion injury, and liver organoids that mitigate fibrosis by repolarizing macrophages toward a proregenerative phenotype. Yet no one had applied the technology to the pleura, despite its unique mesothelial-stromal interface and its vulnerability to mechanical stress during respiratory cycles.

The team, working at Guangdong Medical University, began with mouse lungs. To avoid contamination with deeper parenchymal cells, they isolated intact lungs without cutting, tied off the trachea and suspended the tissue in collagenase solution, carefully controlling digestion between 30 and 60 minutes. Cells recovered from the pleural surface were embedded in Matrigel and cultured in a medium tuned for mesothelial growth, containing R-spondin, EGF, FGF-10 and Noggin alongside pleural maturation additives such as the TGF-beta receptor inhibitor A83-01, ascorbic acid, retinoic acid and dexamethasone, while reducing the epithelial-supporting factors that drive alveolar and airway differentiation. Within a week, the pleural cells formed organoids with thick walls and a central lumen, clearly distinct from the honeycomb-like alveolar clusters produced by matched lung organoids grown from the same animals.

Molecular profiling confirmed the distinction. Pleura organoids expressed markedly less EPCAM, the pan-epithelial marker, and fewer alveolar markers such as AQP5 and SFTPC or airway markers such as CC10 and p63. Instead, they upregulated mesothelin (MSLN) and calretinin, canonical mesothelial markers, along with vimentin, a stromal and fibroblast marker. Enzyme-linked immunosorbent assays showed that the pleura organoids secreted higher levels of phosphatidylcholine and hyaluronic acid, lubricating substances typically produced by mesothelial cells to keep the pleural cavity gliding smoothly. The organoids retained strong Ki67-positive proliferative activity and could be passaged for more than 20 consecutive passages, a scalability that matters for any future clinical application. The protocol adapted readily to human tissue: pleura-covered areas of surgically resected healthy lung, digested with the pleural surface just submerged in collagenase, yielded human organoids with the same thick-walled morphology, mesothelial marker expression and secretory function, sustained by additions such as nicotinamide, prostaglandin E2 and the GSK3 inhibitor CHIR99021.

To test whether the organoids could form pleura-like structures in a living host, the researchers transplanted human pleura organoid cells beneath the kidney capsule of immunodeficient NSG mice. Three weeks later, a well-organized multilayered structure had formed at the graft site, closely resembling the superficial pleural region of human lung tissue. Verhoeff staining revealed organized collagen and elastic fibers, key components of the visceral pleura, and staining for human nuclear antigen confirmed the structures were built by the transplanted cells rather than by mouse tissue. Crucially, the outermost layer consisted of a continuous sheet of mesothelial cells, validating the structural fidelity of the graft.

Functional testing followed. In Transwell wound-healing assays, adding pleura organoid cells to the upper compartment accelerated the closure of scratches in mesothelial monolayers, even when the inflammatory cytokine TNF-alpha was added to mimic the environment of a fresh wound. The researchers then turned to precision-cut lung slices, 200-micrometer sections of intact lung that preserve the visceral pleura and cellular diversity. Notches cut into the pleural surface simulated pleural rupture, and fluorescently labeled human organoid cells were applied dropwise to the injury. Confocal imaging showed the transplanted cells integrating into the damaged area and, within seven days, forming a continuous, dense, multilayered pleura-like structure on the lung surface composed primarily of mesothelin-positive cells.

The decisive experiment came in living animals. The team punctured the visceral pleura of NSG mice through the chest wall to simulate surgical rupture, then delivered human pleura organoid cells into the pleural cavity. Over 35 days, the transplanted mice gained weight steadily while control mice, which received the carrier medium without cells, lost weight before slowly recovering. Histology showed organoid integration into the lung surface as early as day seven, complete filling of the wound, maturation into a dense multilayered structure by day 21 and progressive remodeling into a looser two-to-three-layered organization by day 35, approaching the single-layer architecture of the native pleura. Immunostaining for mesothelin revealed a continuous mesothelial layer on the lung surface by day seven that remained intact and integrated with the host mesothelium through day 35, and co-localization with human nuclear antigen proved the new lining derived from the graft. Barrier function, quantified by injecting fluid into the trachea and measuring the blast volume, the critical threshold at which fluid leaks past the pleura, was significantly higher in transplanted mice at every time point. Inflammation also subsided: TNF-alpha and IL-6 in alveolar lavage fluid, elevated in injured controls even at day 35, approached normal levels in transplanted animals, and expression of alpha-SMA, a fibrosis marker, was significantly attenuated. Histopathology of the heart, liver, spleen and kidney showed no lesions, indicating the therapy was well tolerated.

Mechanistically, the researchers compared organoids that had engrafted and participated in repair with those that had not. Transcriptome sequencing revealed that CD133, also known as PROM1, a stem and progenitor marker never before investigated in mesothelial contexts, was highly expressed in the transplanted organoids. Flow-sorted CD133-positive cells formed larger and more numerous organoids than CD133-negative cells, and the organoids they generated contained mesothelial, epithelial and stromal lineages, demonstrating multilineage potential, whereas CD133-negative cells differentiated only into epithelial cells. RNA sequencing identified 1,457 differentially expressed genes between the populations, with CD133-positive cells upregulating stemness-associated genes and enriching pathways tied to cell division and distinct metabolic programs. A simplified lineage-tracing experiment tracked mesothelin expression over seven days: CD133-positive organoids showed minimal mesothelin on day one, detectable levels by day three and widespread expression by days five and seven, while CD133-negative cells almost completely failed to become mesothelial cells under identical conditions. Single-cell RNA sequencing of more than 116,000 human lung cells independently confirmed a distinct CD133-positive stem cell subpopulation, positioned at a terminal point of a pseudotime differentiation trajectory, with CD133 expression progressively increasing along the trajectory, and immunostaining localized CD133-positive cells along and adjacent to the pleura in both human and mouse lung under homeostatic conditions.

When CD133-positive and CD133-negative organoids were transplanted into mice with pleural rupture, the difference was stark. CD133-positive grafts nearly maintained body weight, formed larger grafts that continuously covered the pleural wound, markedly increased blast volumes, remodeled collagen and elastic fibers and significantly reduced TNF-alpha and IL-6, while CD133-negative grafts showed only limited repair. In the regenerated tissue, CD133-positive cells co-expressed mesothelin in the surface layer, suggesting direct contribution to mesothelial formation, although the authors note that definitive in vivo lineage tracing is still needed to confirm direct differentiation. The work establishes the first pleura organoid models, identifies CD133-positive cells as a previously unrecognized regenerative population and offers a proof of concept for a progenitor-driven therapy that could one day be personalized: pleural biopsies from patients could generate autologous organoids, mitigating immune rejection while restoring pulmonary homeostasis after surgery.

Subject of Research: Regenerative Medicine

Article Title: Pleura organoid transplantation facilitates visceral pleural repair through CD133+ progenitor cell-mediated regeneration

Article References: Deng, B., Huang, P., Wang, Q., He, Y., Gong, L., Chen, C., Wu, Y., Lu, Z., & Liang, Z. (2026). Pleura organoid transplantation facilitates visceral pleural repair through CD133+ progenitor cell-mediated regeneration. Experimental & Molecular Medicine, 58(9), 2990-3006. https://doi.org/10.1038/s12276-026-01825-w

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01825-w

Keywords: organoids, pleura, CD133, progenitor cells, persistent air leak, mesothelium, lung repair, transplantation, thoracic surgery, regenerative medicine, organoid, facilitates

The study, published in Frontiers in Medicine by a team from Bengbu Medical University in China, mined a large perioperative database called INSPIRE, which contains detailed records from Seoul National University Hospital covering operations performed between 2011 and 2020. The researchers focused on 2,665 patients who underwent lung cancer resection and asked a deceptively simple question: does the difference between the carbon dioxide level measured in arterial blood and the carbon dioxide level measured at the end of each breath — the so-called arterial-to-end-tidal gradient — predict postoperative respiratory complications?

To understand why this gap matters, it helps to know what each number represents. The end-tidal carbon dioxide reading, displayed continuously on every anesthesia monitor, reflects the concentration of carbon dioxide in exhaled air at the very end of a breath, which normally approximates the level in the alveoli deep in the lungs. The arterial value, obtained from blood samples, reflects what is actually circulating in the bloodstream. In a healthy lung, these two numbers track each other closely. But when parts of the lung are poorly perfused with blood, or when air and blood flow become mismatched across different regions of the lung, the two readings drift apart. The wider the gap, the more inefficient the gas exchange — and during lung surgery, where one lung is often deliberately collapsed to give surgeons room to work, that mismatch can be dramatic.

The researchers paired each arterial blood gas measurement taken during surgery with the nearest end-tidal reading within ten minutes, then calculated each patient’s median gradient across the operation. Among the 2,436 patients with complete data, 80 experienced respiratory morbidity — either a new respiratory diagnosis such as pneumonia or acute respiratory failure, or a record of postoperative ventilation lasting at least six hours after leaving the operating room. The numbers were striking: for every 5 millimeters of mercury that the gradient rose, the odds of respiratory morbidity increased by 53 percent, and the absolute risk climbed from 2.28 percent in the lowest quartile of gradients to 3.46 percent in the highest — a difference of 1.18 percentage points.

What makes the finding particularly compelling is how robust it proved to statistical scrutiny. The team ran 108 different sensitivity analyses, varying how the gradient was calculated, how the outcome was defined, and which confounding factors were adjusted for. Every single specification produced a positive association. The effect held up when the researchers added operation duration, blood pressure, tidal volume, oxygen fraction, and positive end-expiratory pressure to their models. It held when they excluded whole-lung resections, when they restricted ventilation records to a narrower time window, and when they removed the most statistically influential patients from the analysis. The association was also visible in repeated-measurement models that treated each arterial-end-tidal pair as a separate observation, and in an empirical-Bayes analysis that estimated each patient’s underlying gradient level under standardized conditions.

But here is where the story takes a more sobering turn. When the researchers asked whether the gradient added anything beyond what the arterial carbon dioxide level alone could tell them, the answer was essentially no. In a post hoc analysis, adding the gradient to a prediction model that already included arterial carbon dioxide and clinical covariates changed the cross-validated area under the receiver operating characteristic curve from 0.7324 to 0.7325 — a difference of one ten-thousandth, with a confidence interval that comfortably included zero. The gradient’s statistical advantage over arterial carbon dioxide alone, measured by the Akaike information criterion, was negligible. In other words, the gradient is associated with respiratory morbidity, but it does not appear to carry independent prognostic information once you already know the arterial value.

This distinction matters enormously for clinical practice. End-tidal carbon dioxide is measured continuously and noninvasively on every anesthetized patient, while arterial blood gases require needle sticks and laboratory processing. If the gradient had added meaningful predictive power, it could have become a cheap, real-time early warning system. Instead, the study’s authors are careful to frame their finding as an observational association rather than a clinical tool. They note that the gradient is not equivalent to physiological dead space — the fraction of each breath that reaches airways where no gas exchange occurs — which requires volumetric capnography to measure properly. The Bohr and Enghoff equations used to calculate dead space rely on different measurements entirely, and findings from critical care studies linking dead-space fraction to mortality in acute respiratory distress syndrome cannot simply be transplanted to the operating room.

The physiological story behind the association remains plausible even if the incremental predictive value is modest. Arterial carbon dioxide reflects the balance between metabolic carbon dioxide production and effective alveolar ventilation, while end-tidal carbon dioxide is additionally shaped by regional lung perfusion, the sequence in which different lung units empty, and the technical details of gas sampling. During one-lung ventilation, when an entire lung is collapsed and perfusion is redirected, the gradient can swing widely. Studies dating back decades have documented this variability, and more recent work has shown that end-tidal carbon dioxide tracks changes in cardiac output during hemodynamic shifts. The gradient may therefore be capturing something about pulmonary perfusion and ventilation-perfusion matching that neither number alone reveals — even if that something overlaps substantially with what arterial carbon dioxide already tells us.

The study has important limitations that the authors acknowledge candidly. Arterial sampling was sparse and unstandardized: nearly 44 percent of patients contributed only one arterial-end-tidal pair, and more than three-quarters contributed no more than two. The timing and duration of one-lung ventilation were not recorded, so individual measurements could not be assigned to specific phases of surgery. The outcome definition relied on administrative codes and ventilation records rather than clinical adjudication, meaning both false positives and false negatives are possible. The database could not distinguish planned from unplanned postoperative ventilation, or invasive from non-invasive support. And because the analysis was retrospective and reconstructed after data access, without preregistration, the findings should be treated as hypothesis-generating rather than definitive.

What emerges from this study is a nuanced picture of a familiar monitoring signal. The arterial-to-end-tidal carbon dioxide gradient is associated with postoperative respiratory morbidity after lung cancer resection, and that association survives an unusually thorough battery of sensitivity analyses. But the gradient does not outperform the simpler and more widely available arterial carbon dioxide measurement when it comes to actually predicting who will develop complications. The authors call for prospective studies with standardized arterial gas sampling at defined operative phases, direct measurement of dead space and pulmonary perfusion, and independent external validation before the gradient finds a place in clinical decision-making. Until then, the gap between two numbers on the anesthesia monitor remains a fascinating physiological window into lung function during surgery — one that tells us something real about respiratory risk, even if it does not yet tell us anything we could not learn another way.

Subject of Research: Perioperative medicine and anesthesiology

Article Title: Higher intraoperative arterial-to-end-tidal carbon dioxide gradients are associated with postoperative respiratory morbidity after lung cancer resection: a retrospective INSPIRE cohort study

Article References: Li, L., Wang, D., Zhou, Q., & Shang, B. (2026). Higher intraoperative arterial-to-end-tidal carbon dioxide gradients are associated with postoperative respiratory morbidity after lung cancer resection: a retrospective INSPIRE cohort study. Frontiers in Medicine, 13, Article 1995794. https://doi.org/10.3389/fmed.2026.1995794

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1995794

Keywords: lung cancer surgery, carbon dioxide gradient, capnography, postoperative respiratory morbidity, anesthesiology, thoracic surgery, INSPIRE database, perioperative risk, Higher, intraoperative, arterial-to-end-tidal, carbon

The research team, led by Yongming Wu and colleagues at West China Hospital of Sichuan University, pooled data from thirty studies that had examined the relationship between preoperative serum CEA and hidden nodal spread. The analysis was registered prospectively in PROSPERO, followed PRISMA reporting standards, and searched PubMed, Embase, Web of Science and the Cochrane Library from their inception through 18 March 2026. Rather than relying on a single study’s experience, the investigators used random-effects meta-analysis with restricted maximum likelihood estimation, a statistical framework designed to accommodate the genuine heterogeneity that arises when different hospitals, patient populations and laboratory assays are combined into one evidence base.

The headline numbers are striking. When CEA was treated as a dichotomous variable, meaning patients were classified as either above or below a laboratory cut-off value, the pooled univariate odds ratio for occult lymph node metastasis was 4.82, with a 95 percent confidence interval of 3.66 to 6.36. In plain terms, patients with an elevated preoperative CEA had nearly five times the odds of harboring undetected lymph node involvement compared with those whose levels were normal. When the researchers adjusted for other clinical factors in multivariate models, the association weakened but remained robust, with an adjusted odds ratio of 2.74. The fact that the signal survives statistical adjustment for competing variables is what elevates this finding from a statistical curiosity to something a clinician might actually act upon.

The analysis went further by treating CEA as a continuous variable, asking whether each incremental rise in the marker corresponded to a measurable increase in risk. It did. Every 1-ng/mL increase in preoperative CEA was associated with higher odds of occult nodal metastasis, with a multivariate odds ratio of 1.14 per unit increase and remarkably tight confidence intervals of 1.10 to 1.18. Notably, the heterogeneity statistic for this continuous-variable multivariate analysis was low, at I² of just 10.33 percent, suggesting that this dose-response relationship was unusually consistent across the included studies. The prediction interval, which estimates where the true effect would fall in a new study, remained above the null value, reinforcing confidence that the association is real rather than an artifact of pooling.

Perhaps the most surgically relevant insight came from separating hidden metastases by their anatomical location. Occult disease in N2 nodes, the mediastinal stations that sit centrally in the chest and whose involvement dramatically changes staging and treatment, showed the strongest association with elevated CEA, with a univariate odds ratio of 5.14 and low heterogeneity. Occult N1 disease, involving the hilar and lobar nodes closer to the tumor, was also associated with elevated CEA but with more modest and more variable effect estimates. For thoracic surgeons, this distinction is consequential. N2 involvement discovered after the fact can trigger adjuvant therapy, revision of the surgical plan, or both, and knowing preoperatively which patients carry this risk could reshape how invasive the initial nodal evaluation should be.

Subgroup analyses stratified by clinical stage, tumor size, histological type, CEA cut-off value and country revealed significant positive associations in most strata where enough studies existed to permit pooling. Meta-regression identified histological type as a particularly influential moderator, explaining 51.3 percent of the between-study heterogeneity, with country explaining a further 36.5 percent. The signal was especially pronounced in lung adenocarcinoma, the most common histological subtype of non-small cell lung cancer and one that is known biologically to express CEA more readily than squamous cell carcinoma. Publication year, by contrast, explained none of the heterogeneity, indicating that the association has not strengthened or faded as diagnostic technology has evolved over the decades covered by the included cohorts.

Skeptics of meta-analysis often worry that a single influential study could be propping up the entire result, or that journals have quietly buried studies that found nothing. The authors addressed both concerns directly. Leave-one-out analyses, in which each study is removed in turn and the pooled estimate recalculated, produced odds ratios ranging only from 4.54 to 5.17, a narrow band that speaks to the stability of the primary result. Egger’s regression test, a standard probe for funnel plot asymmetry caused by selective publication, returned a p-value of 0.819, indicating no detectable publication bias. These robustness checks do not guarantee the finding is unassailable, but they place it on considerably firmer footing than many biomarker associations that have entered surgical folklore without equivalent scrutiny.

The clinical context explains why this matters. Preoperative staging of lung cancer currently leans on computed tomography and, increasingly, positron emission tomography combined with CT, yet both modalities have limited sensitivity for nodal involvement, particularly in small tumors where involved nodes may be normal in size and only faintly metabolically active. Current guidelines therefore recommend invasive mediastinal staging for many patients, but uptake varies widely, and even endobronchial ultrasound-guided sampling can miss micrometastatic disease. A cheap, universally available serum test that flags patients at nearly fivefold elevated odds of hidden spread could help prioritize who receives the most thorough invasive staging, who warrants careful intraoperative lymph node dissection, and who might be candidates for neoadjuvant strategies in the future.

There are important caveats, and the authors are candid about them. Every cohort included in the meta-analysis came from East Asian populations, which raises genuine questions about external validity, since baseline CEA levels, smoking patterns, tumor genetics and histological distributions differ across populations. The meta-regression finding that country itself was a significant moderator underscores this concern rather than resolving it. The authors explicitly call for external validation in other populations before the association can be considered universally applicable. They also emphasize that CEA alone is neither sensitive nor specific enough to serve as a standalone staging test; instead, they advocate for combined predictive models that integrate CEA with imaging characteristics, clinical variables and potentially other biomarkers to improve preoperative prediction of nodal involvement.

Even with those limitations, the study represents a meaningful step toward precision in early lung cancer management. CEA is already measured routinely in many thoracic oncology programs, costs pennies compared with PET imaging, and carries none of the risks of invasive staging procedures. The meta-analysis, funded by the Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation and the Postdoctoral Research Fund of West China Hospital, converts a scattered literature into a quantified, graded association with transparent uncertainty estimates, including prediction intervals that acknowledge what a future study might reasonably find. If external validation in Western and other populations confirms the signal, the humble preoperative blood draw could become a standard triage tool, ensuring that the patients whose scans look clean but whose blood tells a different story receive the surgical thoroughness their disease demands.

Subject of Research: Association between preoperative serum CEA and occult lymph node metastasis in clinical stage I non-small cell lung cancer

Article Title: Association between preoperative carcinoembryonic antigen and occult lymph node metastasis in clinical stage I non-small cell lung cancer: a meta-analysis

Article References: Wu, Y., Zhang, Y., Li, J., Che, G., & Jiang, L. (2026). Association between preoperative carcinoembryonic antigen and occult lymph node metastasis in clinical stage I non-small cell lung cancer: a meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17151-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17151-3

Keywords: carcinoembryonic antigen, occult lymph node metastasis, non-small cell lung cancer, meta-analysis, lung adenocarcinoma, biomarker, cancer staging, thoracic surgery, N2 metastasis, predictive marker, PET/CT, serum tumor marker

The concept of textbook outcome is deceptively simple. It is a composite quality benchmark that is satisfied only when every element of a surgical episode goes ideally: the operation achieves an R0 resection, meaning the tumor and its margins are completely removed with no residual cancer visible to the pathologist; an adequate number of lymph nodes is dissected and examined so that staging is reliable; and the perioperative period passes without significant complications, readmission, or prolonged hospitalization. If any single component fails—a positive margin, an insufficient nodal sample, an anastomotic leak, a prolonged air leak requiring reintervention—the textbook outcome is not achieved. The measure originated in surgical oncology as a way to capture quality of care in a single, patient-centered metric rather than a scatter of separate indicators, and it has since been validated in esophageal, pancreatic, colorectal, and gastric cancer surgery. Its application to non-small cell lung cancer treated with neoadjuvant therapy, however, had remained underexplored until now.

The study team, led by researchers at Fujian Medical University Union Hospital together with collaborators at six tertiary hospitals across Fujian Province, China, retrospectively analyzed 347 patients with non-small cell lung cancer who underwent curative-intent resection between 2015 and 2022 after receiving neoadjuvant therapy. Neoadjuvant treatment—chemotherapy, immunotherapy, or chemoradiotherapy delivered before surgery—has become a cornerstone for locally advanced disease, increasingly incorporating immune checkpoint inhibitors that target the PD-1 and PD-L1 pathways. But the preoperative drugs add complexity: they can alter tissue planes, inflame the operative field, and influence both pathological response and surgical difficulty. The researchers asked whether the composite textbook outcome measure could cut through this complexity and deliver prognostic information that conventional measures miss.

The headline finding was that 278 of the 347 patients, or 80.1 percent, achieved a textbook outcome. That figure is itself informative: even in experienced tertiary centers, roughly one in five patients treated with neoadjuvant therapy before lung resection experienced at least one deviation from the ideal surgical pathway. Using logistic regression, the team identified two independent predictors of failure. The first was a Charlson comorbidity index of 3 or higher, a weighted score that quantifies a patient’s burden of pre-existing conditions such as severe cardiac disease, chronic pulmonary disease, diabetes with end-organ damage, or renal impairment. The second was ypN-positive disease—evidence that cancer had persisted in the regional lymph nodes despite the preoperative treatment. Both factors make intuitive sense. Patients with multiple comorbidities have less physiological reserve to weather surgical stress, while residual nodal disease often reflects more aggressive biology and more extensive, technically demanding dissections.

The survival analysis yielded the study’s most consequential result. After multivariable adjustment for competing risk factors, failure to achieve a textbook outcome was independently associated with shorter overall survival, with a hazard ratio of 1.61 and a 95 percent confidence interval of 1.02 to 2.52, reaching statistical significance at P equal to 0.039. In practical terms, patients whose surgical course deviated from the textbook ideal faced roughly a 60 percent higher hazard of death during follow-up compared with those who achieved it. The association with disease-free survival, by contrast, did not reach statistical significance, with a hazard ratio of 1.33 and a confidence interval spanning 0.88 to 2.01 at P equal to 0.180. The authors interpret this asymmetry carefully: the composite metric appears to capture not only oncological completeness but also the physiological toll of a complicated recovery, which may weigh more heavily on long-term overall survival than on the timing of cancer recurrence alone.

Perhaps the most clinically provocative finding concerned adjuvant therapy delivery. Postoperative treatment—additional chemotherapy, radiation, or immunotherapy given after recovery from surgery—is a critical lever for improving outcomes in patients at high risk of recurrence. Yet the study found that patients who achieved a textbook outcome were far more likely to receive adjuvant therapy than those who did not: 72.3 percent versus 46.4 percent, a difference that was highly significant. Even after statistical adjustment, failure to achieve a textbook outcome remained strongly associated with a lower likelihood of receiving adjuvant treatment, with an odds ratio of 0.28. This creates what the researchers describe as a concerning cascade: the very patients whose complicated recoveries signal higher risk are also the patients most likely to fall through the cracks of postoperative treatment, whether because of prolonged convalescence, clinician hesitancy, patient frailty, or logistical barriers that compound one another.

The study also tackled a question at the frontier of thoracic oncology: how the textbook outcome measure relates to major pathological response, or MPR. MPR is defined as the presence of 10 percent or fewer viable tumor cells in the resected specimen and has emerged as a leading surrogate endpoint in trials of neoadjuvant immunotherapy, because it reflects how completely the preoperative drugs eradicated the cancer. But MPR says nothing about the surgery itself or the recovery. The researchers therefore constructed a combined stratification that crossed MPR status with textbook outcome status. The analysis revealed distinct prognostic groups—patients who achieved both fared best, while discordant groups occupied intermediate positions—demonstrating that pathological response and perioperative recovery carry complementary, non-overlapping information.

The statistical evidence for that complementarity was formalized through model-fit testing. Adding textbook outcome to a prognostic model built on MPR alone significantly improved the fit for both overall survival and disease-free survival, with P values of 0.004 and 0.029 respectively, as assessed by likelihood-based criteria including the Akaike information criterion. In plain language, a model that knows only how the tumor responded to drugs is measurably less informative than one that also knows whether the operation and recovery proceeded without incident. This argues for a two-axis approach to postoperative risk assessment: one axis describing the biology of the residual disease, the other describing the quality and consequences of the surgical episode itself.

The implications for clinical practice are tangible. First, textbook outcome could serve as a practical quality-improvement target for thoracic surgery programs, since its component criteria—R0 resection, adequate nodal dissection, uncomplicated recovery—are auditable in routine records. Second, the strong link between failing to achieve the composite endpoint and reduced adjuvant therapy delivery suggests a concrete intervention point: patients who experience perioperative complications or incomplete resections should be flagged for dedicated follow-up to ensure that adjuvant treatment decisions are actively revisited once they recover, rather than quietly abandoned. Third, the combined MPR–textbook outcome framework offers a more nuanced postoperative risk stratification tool that could guide trial design and, eventually, individualized surveillance intensity.

The authors and commentators alike caution that the retrospective design imposes limits. The cohort was drawn from six tertiary hospitals in a single Chinese province, and patterns of perioperative care, adjuvant treatment selection, and follow-up may differ elsewhere. Retrospective analyses are also vulnerable to residual confounding: unmeasured factors—tumor molecular characteristics, specific neoadjuvant regimens, surgeon volume, patient preferences—could influence both the likelihood of a textbook outcome and survival. The authors note that the study was approved by the Institutional Ethics Review Board of Fujian Medical University Union Hospital and conducted under the Declaration of Helsinki, with informed consent waived for the anonymized retrospective data. Prospective validation in diverse populations, and ideally in the context of ongoing immunotherapy-era trials, will be needed before textbook outcome becomes a standard element of postoperative decision-making in lung cancer. Still, the study makes a compelling case that the road to better lung cancer outcomes runs not only through shrinking tumors before surgery, but through ensuring that the operation and its aftermath unfold exactly as the textbook says they should.

Subject of Research: Prognostic value of textbook outcome in resected non-small cell lung cancer after neoadjuvant therapy

Article Title: Prognostic value of textbook outcome in resected non-small cell lung cancer after neoadjuvant therapy: a multicenter retrospective study

Article References: Huang, J., Lin, T.-Z., Wang, Z.-J., He, L.-P., Tu, J.-H., Lian, L.-Y., Jin, Z.-W., Wang, H.-J., Shen, G.-Y., Xu, S.-J., & Chen, S.-C. (2026). Prognostic value of textbook outcome in resected non-small cell lung cancer after neoadjuvant therapy: a multicenter retrospective study. BMC Cancer. https://doi.org/10.1186/s12885-026-17131-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17131-7

Keywords: non-small cell lung cancer, textbook outcome, neoadjuvant therapy, major pathological response, adjuvant therapy, overall survival, disease-free survival, R0 resection, lymph node dissection, perioperative complications, prognosis, thoracic surgery

The research, led by Yehong Li and colleagues at Shandong Second Medical University, Qilu Hospital of Shandong University, and the First Affiliated Hospital of Shandong First Medical University, took on three of the most consequential perioperative outcomes: postoperative complications, a prolonged stay in the hospital after surgery, and moderate-to-severe postoperative pain. Rather than treating these outcomes as a single fuzzy notion of surgical risk, the team built a dedicated prediction model for each, trained on data from 726 patients who underwent surgery for pathologically confirmed thymic epithelial tumors across two Chinese hospitals.

The design of the study reflects a growing awareness in the medical machine learning community that a model’s real test is not how well it performs on the data it learned from, but how it fares on patients it has never seen. The researchers split their cohort geographically and institutionally: the majority of patients, drawn from Qilu Hospital, served as the development and internal validation set, while 169 patients from the First Affiliated Hospital of Shandong First Medical University formed a completely independent external validation cohort. This dual-center structure is considered a gold standard of sorts in prediction modeling, because it exposes whether a model has genuinely learned generalizable biology and physiology, or merely the quirks of one hospital’s record-keeping.

Before any algorithm was trained, the team confronted a problem familiar to every medical data scientist: too many candidate variables, many of them redundant or noisy. Their solution was least absolute shrinkage and selection operator regression, universally abbreviated as LASSO, a statistical technique that compresses the influence of uninformative features toward zero and effectively performs variable selection and regularization in a single step. Out of the preoperative variables available in the records, LASSO distilled 26 predictors for postoperative complications, 14 for prolonged length of stay, and 13 for moderate-to-severe pain. The shrinking variable counts hint at an important hierarchy: complications are the most complex phenomenon, influenced by the widest web of factors, while pain, though clinically significant, appears to be governed by a narrower and harder-to-predict set of circumstances.

With predictors selected, the researchers compared candidate algorithm families and let performance decide. For postoperative complications and prolonged hospital stay, neural-network models emerged as the best performers, their layered architecture well suited to capturing nonlinear interactions among demographic, clinical, laboratory, and imaging variables. For postoperative pain, a decision-tree model won out, a simpler structure that partitions patients into risk branches through a sequence of yes-or-no questions. The contrast is instructive: more complex models are not always better, and for some outcomes, interpretable tree-based approaches can match or exceed their fancier cousins while remaining easier for clinicians to reason about.

The headline numbers come from the area under the receiver operating characteristic curve, or AUC, a measure of how well a model distinguishes patients who experience an outcome from those who do not, with 0.5 representing coin-flip performance and 1.0 representing perfect discrimination. In training cross-validation, internal validation, and external validation respectively, the complication model achieved AUCs of 0.824, 0.814, and 0.775; the prolonged length-of-stay model posted 0.824, 0.809, and 0.776; and the pain model reached 0.695, 0.734, and 0.660. The external validation confidence intervals, spanning 0.658 to 0.892 for complications, 0.697 to 0.855 for prolonged stay, and 0.570 to 0.749 for pain, tell a candid story of both promise and limits.

That story deserves unpacking. A drop from roughly 0.82 in internal testing to about 0.78 in external validation is modest by the standards of clinical prediction models, where performance often collapses far more dramatically when a model crosses hospital boundaries. It suggests the models captured genuine, transportable patterns in how thymic tumor patients recover. The pain model, however, sits closer to the boundary of clinical usefulness, with an external AUC of 0.660 and a confidence interval whose lower edge nearly touches the uninformative 0.570 mark. Pain, the authors’ results imply, is shaped by factors that preoperative data alone cannot fully capture, from intraoperative surgical decisions to individual pain perception and psychology. The team was transparent about this, noting that further multicenter prospective validation is required before any clinical implementation, a caveat that responsible readers should take seriously.

One of the study’s most forward-looking contributions lies in how the models explain themselves. Black-box predictions have been a persistent barrier to clinical adoption, and the researchers addressed it with Shapley-based attribution analysis, a technique borrowed from cooperative game theory that assigns each input variable a quantified share of responsibility for any individual prediction. By computing Shapley values across the cohort, the team could identify which preoperative factors pushed individual patients toward higher or lower risk, transforming an opaque neural network into something a surgeon can interrogate. This kind of interpretability layer is increasingly viewed as essential for medical artificial intelligence, both for building clinician trust and for meeting regulatory expectations that high-stakes algorithms justify their outputs.

The practical delivery vehicle for all of this is a web-based calculator that visualizes the models’ predictions, allowing a clinician to enter a specific patient’s preoperative characteristics and receive individualized risk estimates for complications, prolonged stay, and pain. Such tools sit at the intersection of statistics and bedside decision-making: they could inform the timing and intensity of postoperative monitoring, guide conversations with patients about what to expect, shape decisions about analgesic planning, and help allocate intensive care resources to those most likely to need them. For a rare tumor like thymic epithelial neoplasm, where no single center sees large volumes and clinical intuition is built on limited experience, a validated quantitative aid carries particular value.

The study also arrives amid a broader shift in how surgical oncology thinks about risk. Traditional risk scoring systems, often built with logistic regression on single-center data, have struggled to capture the heterogeneous recovery trajectories of mediastinal tumor patients. Machine learning approaches, with their capacity for nonlinear interactions and their emphasis on external validation and interpretability, represent a methodological upgrade, but the Shandong team’s work illustrates both the potential and the discipline required. The models are strong but not infallible, the pain prediction remains the weakest link, and the retrospective design means the algorithms learned from records collected for care rather than for modeling. The authors’ own framing, that prospective multicenter validation must come first, is the right one. If those validations succeed, the day may not be far off when a patient with a thymic epithelial tumor can be told, before surgery, a data-driven estimate of what their recovery will look like, and when the surgical team can prepare accordingly. That would turn one of thoracic surgery’s lingering uncertainties into a calculable risk, and calculable risks are the kind medicine knows how to manage.

Subject of Research: Machine learning prediction of perioperative outcomes in thymic epithelial tumor surgery

Article Title: Development and validation of machine learning models for preoperative prediction of perioperative outcomes in patients with thymic epithelial tumors

Article References: Li, Y., Qiu, J., Zhao, Y., Jin, K., Li, Y., & Tian, H. (2026). Development and validation of machine learning models for preoperative prediction of perioperative outcomes in patients with thymic epithelial tumors. Scientific Reports. https://doi.org/10.1038/s41598-026-74722-x

Image Credits: AI Generated

DOI: 10.1038/s41598-026-74722-x

Keywords: thymic epithelial tumors, machine learning, postoperative complications, length of stay, postoperative pain, LASSO regression, neural networks, decision tree, SHAP, risk prediction, thoracic surgery, external validation

The research team, led by pediatric surgeons Madeline Adams, Stephanie D. Chao, and Marisa E. Schwab, turned to the MarketScan Commercial Database, a large insurance claims repository that captures detailed billing records from privately insured patients across all fifty states. Using the International Classification of Diseases, Tenth Revision diagnostic codes assigned to congenital lung malformations between 2017 and 2023, the investigators identified affected patients and then required confirmation through cross-sectional chest imaging billed under the corresponding Current Procedural Terminology codes. This two-step approach, pairing a diagnostic code with objective imaging evidence, was designed to filter out coding noise and ensure that the cases counted in the analysis represented genuinely identified malformations rather than administrative artifacts.

The headline number that emerged from the analysis was a prevalence of 2.15 cases per 10,000 patients, which translates roughly into one diagnosed congenital lung malformation for every 4,650 infants in the commercially insured population. That figure may sound modest, but in a nation with roughly 3.6 million annual births it implies thousands of new diagnoses each year, making congenital lung malformations an important index condition for pediatric surgical services. The study also traced how detection changed over the study window: prevalence climbed from 1.80 per 10,000 in 2017 to a peak of 2.67 per 10,000 in 2020 before settling back in subsequent years. Intriguingly, when the researchers built a multivariate model adjusting for other factors, the year of birth itself was no longer a statistically significant predictor of diagnosis, suggesting that the apparent rise and fall may reflect shifting screening practices, coding conventions, or the disruptions of the COVID-19 pandemic era rather than a true change in the underlying biology.

One of the most striking findings in the adjusted model concerned geography. Infants living in the Southern United States were significantly less likely to be diagnosed with a congenital lung malformation than infants elsewhere in the country, with an adjusted prevalence ratio of 0.72 and a 95 percent confidence interval of 0.53 to 0.97, a difference the authors reported as statistically significant at p equals 0.03. In practical terms, this means that after accounting for other variables, babies in the South were diagnosed at roughly 28 percent lower rates than their counterparts in other regions. The study did not identify the mechanism behind this disparity, but the possibilities are consequential: differences in prenatal screening uptake, access to high-resolution fetal ultrasound and fetal magnetic resonance imaging, referral patterns to pediatric surgical centers, or variation in insurance coverage and healthcare-seeking behavior could all contribute. Whatever the cause, the authors note that such regional variation carries clear equity implications for which infants get identified and treated early.

Congenital lung malformations encompass several distinct entities, the most commonly discussed being congenital pulmonary airway malformation, formerly known as congenital cystic adenomatoid malformation, along with bronchogenic cysts, pulmonary sequestration, and hybrid lesions that combine features of more than one type. These malformations arise from errors in early embryonic lung development, when the branching airway tree is forming, and they can range from tiny, asymptomatic lesions discovered incidentally to large masses that compress surrounding lung tissue, shift the mediastinum, and cause respiratory distress in newborns. Many are now caught before birth, because routine second-trimester prenatal ultrasound frequently visualizes echogenic or cystic lung lesions, and specialized centers follow suspicious findings with fetal MRI and serial ultrasound measurements. Specialists sometimes calculate a CPAM volume ratio, a measurement that compares the size of the lesion to the fetal head circumference, to stratify the risk of hydrops and guide the intensity of prenatal surveillance.

What happens after diagnosis, however, has been the subject of genuine clinical debate. Some malformations cause trouble immediately, producing breathing difficulty, recurrent infections, or air trapping that demands prompt surgical resection. Others remain silent for years, and for those lesions the question of whether to operate prophylactically, to prevent future infection or, more controversially, to address a small reported risk of malignant transformation, versus pursuing watchful waiting with serial imaging, remains unsettled in the literature. The new study provides a valuable dose of national data on what actually happens in practice: among infants diagnosed with a congenital lung malformation, 47.72 percent underwent surgical resection. In other words, just under half of diagnosed infants had their lesion removed, while the other half were apparently managed without an operation during the observation window, a split that mirrors the ongoing tension between operative and nonoperative management strategies.

Timing of surgery emerged as another clear pattern. Of the infants who did undergo resection, 96.18 percent had their operation during the first year of life, underscoring that when American pediatric surgeons decide to operate on these lesions, they overwhelmingly do so early rather than deferring intervention into later childhood. This preference for early resection reflects several practical considerations: lesions are often easier to remove before they have caused repeated infections or scarring, compensatory lung growth in infancy may be more robust after lobectomy, and families and clinicians alike often prefer to resolve uncertainty while the child is young. Yet the study also detected a trend over the study period toward decreasing resection rates, hinting that the pendulum may be swinging, at least modestly, toward more conservative management as clinicians gain confidence in surveillance protocols for asymptomatic lesions and as shared decision-making with families becomes more common.

Perhaps the most unexpected finding concerned where the operations took place. Among infants who underwent resection, 21.21 percent received their surgical care in a state different from their home state, meaning that more than one in five families crossed state lines for their child’s lung surgery. This migration of care is a powerful signal of how concentrated specialized pediatric surgical expertise has become. Congenital lung resection, whether performed open or thoracoscopically, demands pediatric anesthesiologists, neonatal intensive care capacity, and surgeons with specific thoracic experience, resources that exist at a limited number of children’s hospitals. Families who live far from such centers may travel hundreds of miles, absorbing significant costs and logistical burdens, and the authors point out that this migration may reshape healthcare utilization patterns in ways that policy makers have not fully accounted for. It also raises equity questions, because families with the means, flexible jobs, and insurance networks to travel may access high-volume expert centers while others may not.

The study’s methodology deserves attention from anyone interpreting its numbers. MarketScan captures commercially insured patients, which means the findings may not generalize perfectly to infants covered by Medicaid or the uninsured, populations that skew differently demographically and geographically. Claims data also cannot capture the full clinical picture: the study cannot distinguish reliably among malformation subtypes, cannot measure lesion size or the presence of symptoms, and cannot reveal why any individual family or surgeon chose surgery or surveillance. The prevalence figure of 2.15 per 10,000 is best understood as a diagnosed prevalence within a privately insured population rather than a true birth prevalence of the underlying malformations, since some lesions likely go undetected and some affected pregnancies do not result in live birth. Still, by requiring imaging confirmation and analyzing seven years of national data, the study sets a firmer baseline than the small single-center series that have dominated the literature.

For clinicians, the takeaways are concrete. The declining resection trend suggests that nonoperative management is gaining real-world traction, which should prompt continued development of evidence-based surveillance protocols and longer-term outcome data on children managed without surgery. The regional diagnostic gap in the South is a call to examine prenatal screening access and referral pathways, because a malformation that goes undiagnosed in infancy may still declare itself later with infection or other complications. And the substantial interstate migration for surgery highlights the need for thoughtful regionalization of pediatric thoracic care, paired with support systems that make expert care reachable for families regardless of zip code. As the first contemporary population-based study of its kind in the United States, this analysis does not settle the clinical debates around congenital lung malformations, but it gives the field something it has lacked: a national map of where things stand today, drawn from the real-world experiences of thousands of infants and their families.

Subject of Research: National prevalence and surgical management of congenital lung malformations among US infants

Article Title: A database study of contemporary diagnosis and management among infants with congenital lung malformations in the United States

Article References: Adams, M., Chao, S. D., & Schwab, M. E. (2026). A database study of contemporary diagnosis and management among infants with congenital lung malformations in the United States. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07785-4

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07785-4

Keywords: congenital lung malformations, pediatric surgery, prenatal diagnosis, CPAM, MarketScan database, epidemiology, healthcare disparities, thoracic surgery, infant health, insurance claims data, regionalization of care, BMC Pediatrics

The research, conducted by thoracic surgeons Muhammad Shoaib Nabi and Zeeshan Sarwar of the Department of Thoracic Surgery at Services Institute of Medical Sciences in Lahore, Pakistan, describes a prospective, single-arm educational study carried out between 2006 and 2025 across multiple hospitals in Punjab province. In total, 4,045 participants took part, ranging from medical interns and surgical residents to consultant faculty members. Each attended a structured workshop that combined didactic lectures on the anatomy and physiology of the chest, live demonstrations of correct technique, and supervised hands-on practice inserting chest tubes into the goat chest model. The scale of the program is remarkable for any simulation study, and its duration, spanning nearly two decades, makes it one of the longest-running procedural training initiatives of its kind reported in the surgical education literature.

The choice of a goat chest was not arbitrary. High-fidelity commercial simulators for tube thoracostomy exist, but they are expensive, often costing thousands of dollars, and are rarely available in the hospitals of low- and middle-income countries where the burden of chest trauma is high and training resources are scarce. A cadaveric goat chest, obtained from animals freshly sacrificed for other purposes, offers tissue with realistic resistance: skin that must be incised firmly, intercostal muscles that must be spread with a clamp, parietal pleura that gives way with a characteristic pop, and a pleural cavity deep enough to accept a chest tube. The authors report that participants, drawing on their prior experience with commercially available synthetic manikins in earlier training activities, rated the goat model as highly realistic by comparison. This tactile authenticity matters, because the feel of tissue planes is precisely what novice operators lack and what synthetic models often fail to reproduce.

The educational design of the workshops was straightforward but rigorous. Trainees completed pre-training assessments of knowledge and confidence before the session, then received lectures and demonstrations, and finally performed the procedure themselves under direct faculty supervision. Instructors used structured checklists to score each attempt and to document specific technical errors. After training, the same knowledge and confidence assessments were repeated, allowing the researchers to quantify change within each participant. Of the 4,045 trainees enrolled over the nineteen years, 3,155, or 78 percent, completed the follow-up assessment, a substantial retention rate for a program of this scale and duration.

The results were striking. Mean knowledge scores rose from 4.99 on a ten-point scale, with a standard deviation of 1.16, to 7.98, with a standard deviation of 1.57, a gain that was statistically significant at p less than 0.001. Self-rated confidence climbed even more dramatically, from a mean of 2.0 on a five-point scale to 4.5, again with p less than 0.001. These numbers tell a familiar story in simulation research, but the study goes further by documenting what trainees actually did wrong, and this error analysis is arguably the most valuable contribution of the paper. The most frequent technical error was incorrect site selection, seen in 18 percent of attempts, followed by inadequate dissection through the chest wall in 12 percent and tube misdirection within the pleural space in 10 percent.

These error patterns mirror exactly the complications that plague real-world chest tube insertion. Incorrect site selection risks injury to intra-abdominal organs or major vessels, and published studies have documented clinically significant malposition of chest tubes in a meaningful fraction of critically ill patients. Inadequate dissection means the operator may fail to enter the pleural space at all or may force the tube against unyielding tissue, while misdirection leaves the tube curled against the chest wall or fissure rather than draining the intended space. Under supervision, correct tube placement was achieved in 45 percent of attempts, a figure that may seem modest but reflects the genuine difficulty of the procedure for novices and underscores why repeated, realistic practice before touching a patient is so important. The checklist-based feedback allowed instructors to name each error specifically, converting a failed attempt into a targeted teaching moment.

The study sits within a broader and growing body of evidence on simulation-based procedural training. Previous work has compared synthetic task trainers, human cadavers, and live animal models for chest tube education, with some studies finding that simulator training is associated with faster and more successful real-world performance. Others have explored novel approaches, including biomaterial-covered mannequins, three-dimensional printed thorax models, and even app-based serious gaming as adjuncts to hands-on practice. A systematic review of cadaveric simulation in surgical training has highlighted the enduring value of real tissue for teaching operative skills. The Pakistani study adds an important data point for resource-limited settings, where the question is not which high-end model to buy but how to deliver realistic training at all. In that context, a goat chest costs a fraction of a commercial simulator, requires no specialized equipment beyond standard surgical instruments, and can be sourced locally.

The authors are candid about the framework within which such training must operate. The study protocol was reviewed and approved by the Institutional Review Board of Services Institute of Medical Sciences, Services Hospital, Lahore, under reference number IRB/2025/1668/SIMS, and the researchers declared no conflicts of interest, funding the work through their own efforts. The use of animal tissue in medical education raises ethical questions that institutions must weigh, but the practice of using tissue from animals already sacrificed for food or other purposes is well established in surgical training traditions worldwide, including military and trauma surgery courses that have long used live tissue and cadaveric models to teach emergency procedures. The nineteen-year continuity of the Lahore program suggests that the model found durable institutional acceptance.

What makes this study resonate beyond Pakistan is the global inequity it addresses. Trauma remains a leading cause of death and disability in young people across South Asia, Africa, and other regions where chest injuries from road traffic collisions and violence are common, yet formal hands-on training in chest tube insertion has historically been limited, with many clinicians learning the procedure for the first time on a living patient. Research on surgical resident training in Pakistan has previously identified simulation-based education as an underused resource, and studies of chest tube complications have asked pointedly how well residents are being trained at all. By demonstrating that a simple, affordable biological model can produce measurable gains in knowledge, confidence, and technical performance across more than four thousand trainees, the Lahore team offers a template that other institutions in similar settings can adopt without waiting for expensive equipment.

The findings also carry a humbling message for wealthy health systems. Even with structured teaching, demonstrations, and supervision, only 45 percent of novice attempts achieved correct tube placement, and errors clustered around the same technical pitfalls that injure patients in real emergencies. Simulation does not make a procedure easy; it makes failure safe. The Pakistani program shows that when the barrier of cost is removed, thousands of clinicians can be given the chance to fail, learn, and improve before their skills are needed at a bedside. As surgical education increasingly embraces virtual reality, artificial intelligence, and 3D printing, this nineteen-year experiment with a goat chest is a reminder that the most transformative training technology in a resource-limited hospital may be the one that costs almost nothing and feels exactly like the real thing.

Subject of Research: Simulation-based tube thoracostomy training using a cadaveric goat chest model

Article Title: Outcomes of tube thoracostomy training using a cadaveric goat chest model: a 19-year experience

Article References: Nabi, M. S., & Sarwar, Z. (2026). Outcomes of tube thoracostomy training using a cadaveric goat chest model: a 19-year experience. Global Surgical Education – Journal of the Association for Surgical Education, 5(1), Article 127. https://doi.org/10.1007/s44186-026-00532-4

Image Credits: AI Generated

DOI: 10.1007/s44186-026-00532-4

Keywords: tube thoracostomy, simulation-based training, goat cadaver model, surgical education, chest tube insertion, low-resource settings, thoracic surgery, procedural skills, Pakistan, medical simulation, trauma training, error analysis

The operation at the center of the report is called extended resection of thymic tumor combined with artificial bypass between the innominate vein and the right atrial appendage. In essence, surgeons remove the thymic tumor together with the segment of superior vena cava it has invaded, then restore venous outflow by sewing a synthetic vascular graft between the innominate vein and a small pouch-like structure on the heart called the right atrial appendage. Since March 2016, the Shanghai group has explored this approach systematically. A published study from their institution covering fifty-seven patients treated between January 2016 and June 2021 found that the procedure substantially improved quality of life and prolonged survival. Among those cases, twenty-five patients required resection of the left innominate vein alone, two underwent partial resection and repair of the superior vena cava, and thirty received full artificial vessel reconstruction between the innominate vein and the right atrial appendage before the tumor and the vein were removed.

What makes the new commentary valuable is its focus on the anesthetic discipline that underpins the surgery. The authors, anesthesiologists YuanYuan Ma and ShengJin Ge and thoracic surgeon JianYong Ding, emphasize that the operation demands general anesthesia with a single-lumen endotracheal tube, because access is gained through a median sternotomy, the vertical division of the breastbone. Notably, they deliberately avoid combining general anesthesia with an epidural block, a technique often used for pain control in major chest surgery. The reason is practical and unforgiving: these patients require strict anticoagulation around the time of surgery to keep the artificial graft from clotting, and an epidural catheter in a heavily anticoagulated patient carries a risk of spinal bleeding that no surgical benefit can offset.

Preparation begins long before the first incision. The team insists on a mandatory preoperative assessment of both the airway and the great vessels. In their experience, airway integrity is rarely compromised in patients selected for planned surgery, but the vascular assessment is critical: anesthesiologists and surgeons must map precisely where and how extensively the tumor invades the superior vena cava and the brachiocephalic veins, and they must judge whether collateral circulation, the network of smaller veins that develops to bypass a chronically obstructed great vessel, has already been established. The anatomy itself offers a helpful clue for planning. The left innominate vein crosses in front of the aortic arch and follows a long, accessible course, which makes it relatively easy to separate and expose when the tumor has not completely engulfed it. That is why the left innominate vein to right atrium reconstruction is the team’s preferred configuration.

Once the patient is in the operating room, the monitoring strategy reads like a checklist for protecting two vulnerable organs at once: the brain and the heart. The team tracks body temperature and measures the activated clotting time of whole blood, or ACT, at three key moments: before anesthesia induction, fifteen minutes after giving intravenous heparin at a dose of one milligram per kilogram, and thereafter as needed to guide anticoagulation. Depth of anesthesia is monitored with the bispectral index, including the burst suppression ratio, or alternatively with cerebral oxygen saturation, so that any fall in brain perfusion is caught in real time. A catheter is placed retrograde into the cranial segment of the right internal jugular vein to measure venous pressure on the head side of the obstruction, and transesophageal echocardiography is recommended for patients with significant cardiac disease. Vascular access is equally deliberate: the femoral vein and the left radial artery are catheterized, and the right internal jugular vein is cannulated in reverse, toward the head.

The physiological logic that ties the whole anesthetic plan together is captured in a single number. Intracranial perfusion pressure, the pressure driving blood through the brain, is approximately equal to the difference between the mean arterial pressure and the right internal jugular venous pressure. The team therefore watches both values continuously throughout the operation and afterward, and maintains that difference at greater than sixty millimeters of mercury during the entire perioperative period. When the superior vena cava is clamped, venous pressure on the head side can climb steeply, so the team keeps it below thirty millimeters of mercury based on their accumulated experience, elevates the head of the operating table by fifteen to thirty degrees to encourage venous return, and administers intravenous mannitol when appropriate to reduce cerebral swelling. If the bispectral index shows burst suppression appearing or rising, a signal the authors interpret as cerebral hypoperfusion with ischemia, the response is immediate: raise the perfusion pressure, and if necessary change the mode of superior vena cava reconstruction altogether.

Ventilation during the operation follows the principles of lung-protective mechanical ventilation, adapted to the peculiar hemodynamics of venous clamping. The team uses low tidal volumes of four to six milliliters per kilogram of body weight, compensates with an increased respiratory frequency to keep the end-tidal carbon dioxide partial pressure in the normal range, and applies zero positive end-expiratory pressure. That last choice matters: positive pressure in the chest would impede venous return at precisely the moment when the surgical team is rerouting it. Other details reveal how finely tuned the procedure is. During manipulation of the pericardium, the anesthesiologist watches cardiac function, blood pressure, and arrhythmias closely. After the subclavian vein is blocked, any available upper extremity intravenous route is clamped to prevent infusions from being delivered into a territory with no venous outflow. And before the tumor-invaded superior vena cava is clamped, the team confirms that the patient has no peripherally inserted central catheter or subcutaneous port catheter that could be damaged or dislodge.

The moment the bypass graft is opened is one of quiet confirmation. The team observes whether the pressure in the right internal jugular vein drops significantly, which would indicate that the new conduit is successfully draining blood from the head. Heparin is then partially antagonized with protamine, but not fully reversed: the activated clotting time is maintained at an appropriate prolongation, below two hundred seconds, striking a balance between preventing graft thrombosis and avoiding catastrophic bleeding. Throughout the operation the team monitors bleeding, cardiac function, and central venous pressure measured through the femoral venous line, giving blood transfusion, cardiotonic drugs, or diuretics as the situation demands. Cutaneous congestion over the head, neck, and upper chest is treated as a serious warning sign that venous drainage is failing, and the operating surgeon is notified immediately if it appears.

Even the awakening and handover phases carry their own safeguards. As patients emerge from anesthesia, the team watches brain function, including consciousness and movement, and pays attention to respiration, because the right phrenic nerve, which drives one half of the diaphragm, is often transected during the operation, a loss that generally causes little harm but can affect breathing. One instruction the authors say must never be forgotten at the intensive care unit handover is that the right internal jugular vein catheter is for continuous pressure measurement only, never for infusion, since injecting fluid into that vessel would raise intracranial venous pressure. Finally, every patient receives long-term anticoagulation after surgery to keep the artificial graft open, a commitment that begins in the operating room and continues for life.

The larger message of the commentary extends beyond any single operation. Extended resection of thymic tumors with artificial bypass, the authors conclude, requires not only excellent surgical skill but also appropriate intraoperative anesthesia control and intensive critical care, and multidisciplinary teamwork is mandatory. In an era when tumors once deemed inoperable are increasingly being resected with vascular reconstruction, the Shanghai experience offers a template: a standardized anesthetic protocol built around perfusion pressure mathematics, real-time neuromonitoring, meticulous vascular access planning, and disciplined communication between surgeon and anesthesiologist. For patients facing a tumor that has claimed the body’s largest vein, that template may be the difference between palliative care and a genuine chance at extended survival.

Subject of Research: Anesthesia management for extended resection of thymic tumors invading the superior vena cava with artificial innominate vein to right atrial appendage bypass

Article Title: Anesthesia management for extended resection of thymic tumor combined with artificial bypass between the innominate vein and the right atrial appendage

Article References: Ma, Y., Ding, J., & Ge, S. (2024). Anesthesia management for extended resection of thymic tumor combined with artificial bypass between the innominate vein and the right atrial appendage. Clinical Cancer Bulletin, 3(1), Article 14. https://doi.org/10.1007/s44272-024-00020-0

Image Credits: AI Generated

DOI: 10.1007/s44272-024-00020-0

Keywords: thymic tumor, superior vena cava syndrome, anesthesia management, innominate vein bypass, right atrial appendage, vascular reconstruction, thoracic surgery, activated clotting time, bispectral index, cerebral perfusion pressure, anticoagulation, multidisciplinary surgery

Congenital lung malformations encompass a spectrum of structural abnormalities, including congenital pulmonary airway malformations, in which cyst-like maldeveloped airway tissue replaces normal lung, and pulmonary sequestration, in which a piece of lung tissue lacks a normal connection to the airway and instead receives its blood supply from the systemic circulation. When these lesions occupy the posterior and lateral basal segments of the lower lung lobe, the segments labeled S9 and S10 in the standard anatomical numbering system, surgeons have traditionally faced a choice between removing the entire lobe through a lobectomy or performing a segmentectomy that isolates and removes only the affected segments. Each option carries trade-offs that matter enormously for a growing child.

Lobectomy is technically straightforward and reliably removes the malformation, which is why it has long been the default operation. But a child’s lungs continue to develop throughout childhood, and every gram of healthy parenchyma removed represents tissue that can never contribute to gas exchange. Segmentectomy, by contrast, demands meticulous dissection of the segmental blood vessels, airways, and the invisible planes between adjacent lung segments, but it preserves the superior segment, known as S6, and its vital connection to the remaining basal lung tissue. The team behind the new study, led by surgeons at the Children’s Hospital Affiliated to Shandong University and Jinan Children’s Hospital, set out to determine whether their arch-shaped modification of segmentectomy could make this lung-sparing option safer and more predictable.

The retrospective analysis reviewed the records of 77 children with congenital lung malformations who underwent thoracoscopic surgery between January 2019 and June 2023. The patients were divided into three groups according to the operation they received: 22 children underwent thoracoscopic lobectomy, 33 underwent conventional thoracoscopic S9-10 segmentectomy, and 22 underwent the new “Arch” thoracoscopic S9-10 segmentectomy. The researchers compared perioperative outcomes, postoperative findings, and radiological follow-up across the groups, and they applied the Bonferroni correction to pairwise comparisons, a statistical adjustment designed to reduce the risk of false-positive findings when multiple comparisons are made simultaneously.

The defining feature of the Arch technique lies in how the surgeon shapes the cut across the lung parenchyma. In a conventional segmentectomy, the division of the S9-10 segments can leave a broad, flat raw surface on the remaining lung, and the interface between the resected area and the preserved superior segment can be technically awkward to manage. The Arch approach instead creates an arch-like, curved resection line that follows the natural anatomical boundary between the basal segments and the superior segment. This curved geometry is intended to preserve the connection between S6 and the remaining basal parenchyma more faithfully, maintain the natural contour of the lower lobe, and reduce tension on the staple or suture lines that seal the lung after the diseased tissue is removed.

Every one of the 77 procedures in the study was completed thoracoscopically, meaning the surgeons operated through small incisions using a camera and long instruments rather than opening the chest. There were no conversions to open thoracotomy, no reoperations, no severe complications, and no residual lesion left behind in any patient. That clean safety record across all three surgical approaches is itself a notable finding, because segmentectomy in children is widely regarded as more technically demanding than lobectomy, and the study demonstrates that in experienced hands both conventional and arch-shaped segmentectomy can be completed entirely through keyhole surgery.

When the researchers examined the details of recovery, some expected patterns emerged. Lobectomy was associated with shorter operative time, shorter chest tube duration, and a shorter postoperative hospital stay than either of the segmentectomy procedures, which is consistent with the simpler nature of removing an entire lobe at once rather than dissecting individual segments. Comparing the two segmentectomy techniques directly, the Arch group showed lower mean blood loss than the conventional group, although the authors were careful to note that the absolute difference was small. The difference in operative time between the two segmentectomy groups did not remain statistically significant after adjustment for multiple comparisons, a reminder that apparent advantages seen in raw numbers can dissolve under rigorous statistical scrutiny.

Complications in the series were few and mild. Postoperative air leak, a common and usually self-limiting event in lung surgery in which air escapes from the cut lung surface into the chest drain, occurred in exactly one patient in each of the two segmentectomy groups, and both leaks resolved with drainage alone. In the Arch group, two patients developed a loculated postoperative air collection, meaning a pocket of air became walled off within the chest cavity, but these collections resolved spontaneously within three months without any surgical intervention. No major complications were observed in the Arch group, and the overall perioperative event profile was similar across all three groups in this series.

The authors are explicit that the study’s conclusions must be interpreted with appropriate caution. As a retrospective review, the analysis depends on how patients were selected for each operation in the first place, and the groups were not randomized. The small differences in perioperative outcomes between the techniques should not be overread, particularly given the statistical adjustments and the modest size of the cohorts. What the study does establish, according to its authors, is feasibility: in selected children whose congenital lung malformations are confined to the S9-10 segments, the Arch thoracoscopic segmentectomy can be performed safely, with no major complications observed, and its main potential value lies in preserving the S6-basal segment connection and normal lung parenchyma that a lobectomy would sacrifice.

That preservation may prove to be the technique’s most important legacy. For a child with decades of growth and physical activity ahead, the difference between losing an entire lower lobe and losing only its two most diseased basal segments could translate into meaningfully better lung function, exercise capacity, and quality of life over a lifetime. The research team emphasizes that prospective studies with long-term functional assessment are needed before the Arch technique can be considered a standard of care, and such studies would need to measure not just operative metrics but actual lung growth and function over years of follow-up. Until then, the study stands as an encouraging proof of concept that the geometry of a surgical resection line, shaped like an arch to respect the lung’s natural architecture, may help surgeons remove disease while giving healthy tissue every chance to thrive.

Subject of Research: Arch-shaped thoracoscopic segmentectomy for congenital lung malformations in children

Article Title: Arch-like thoracoscopic posterior and lateral basal segmentectomy for congenital lung malformations in children

Article References: Guo, R., Zhang, S., Zhai, Y., Zhao, H., Cui, R., & Li, J. (2026). Arch-like thoracoscopic posterior and lateral basal segmentectomy for congenital lung malformations in children. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07655-z

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07655-z

Keywords: congenital lung malformations, thoracoscopy, segmentectomy, pediatric surgery, minimally invasive surgery, lung-preserving surgery, lobectomy, S9-10 segments, pulmonary sequestration, CPAM, thoracic surgery, BMC Pediatrics

The report, led by interventional radiologist Charlie A. Hamm and colleagues, is framed as a technical roadmap rather than a large trial, but its results are striking in their consistency. Eleven patients, four women and seven men ranging in age from 34 to 77, underwent CT-guided dye-based marking of twelve lung nodules before minimally invasive, lung-sparing resection. The median nodule diameter was just 8.5 millimeters. Every single marking procedure was technically successful, every lesion was completely resected, and no operation had to be converted to open surgery or an entire lobectomy because the surgeon could not find the target. Seven of the twelve lesions turned out to be malignant, underscoring how much rides on getting the localization right.

The clinical backdrop explains why this matters. Randomized screening trials such as the Dutch-Belgian NELSON study showed that volume-based CT screening reduces lung cancer mortality, and more recent cohort work like the SUMMIT study has confirmed that the majority of screen-detected cancers are diagnosed at stage I or II, when surgery is the primary treatment. That shift has pushed thoracic surgeons toward sublobar resection, removing a wedge of lung or a single segment rather than the whole lobe, to preserve as much healthy parenchyma as possible. But the smaller the lesion and the more tissue-sparing the operation, the more critical it becomes to know exactly where the target sits before the first incision is made.

The traditional answer has been the hook-wire, a thin barbed wire placed through the chest wall into or next to the nodule on the morning of surgery. Hook-wires work, but they come with real drawbacks. They typically force same-day scheduling of two procedures, they can dislodge or migrate before the surgeon reaches them, and a rigid wire protruding through the pleura is uncomfortable and potentially hazardous for the patient, who must be transported carefully to avoid tearing lung tissue. The Berlin team’s dye-based approach eliminates the transpleural hardware entirely, which the authors note has been reported to cause less patient discomfort and stress and reduces the risk of marker displacement.

The first of the two dye techniques relies on patent blue V, a synthetic triphenylmethane dye that has long been used to trace lymphatic drainage in breast surgery and melanoma staging. It is water-soluble, renally excreted, and has a low toxicity profile, with allergic reactions occurring in fewer than one percent of patients. Under CT-fluoroscopic guidance, the radiologist advances a fine 22-gauge Chiba needle until its tip sits immediately adjacent to the nodule, deliberately avoiding puncture of the lesion itself, which reduces the theoretical risk of tumor seeding along the needle track and avoids compromising the pathology specimen. Then 0.1 to 0.4 milliliters of dye is injected through a small Luer-lock syringe, and the needle is withdrawn promptly without a saline flush, which would dilute the dye and could tattoo the skin along the exit path.

What happens next is a matter of physics and anatomy. The dye diffuses through the terminal vascular bed of the lung and reaches the pleural surface, where it creates a sharply demarcated blue patch that tells the surgeon precisely where the resection margin should fall. If the lesion lies more than three centimeters beneath the pleura, the dye is injected in increments as the needle is withdrawn, leaving a stained tract running from the nodule toward the chest wall. Because patent blue V gradually disperses into the bloodstream and pleural fluid, the color fades within hours, so surgery must be scheduled the same day, ideally within three hours of the marking. In the Berlin series, the five patients who received patent blue V injections had a median marking time of just seven minutes.

The second technique solves the fading problem with indocyanine green, or ICG, a tricarbocyanine fluorescent dye that binds readily to tissue proteins and glows bright emerald green when excited by near-infrared light. Injected alone, ICG diffuses more slowly than patent blue V and can remain visible in lung tissue for up to six days, a finding documented in prior experimental work. More importantly, near-infrared light penetrates soft tissue far better than visible light, so a fluorescence camera in the operating room can detect the glowing signal from millimeters to several centimeters beneath the pleural surface, effectively letting the surgical team see through the lung’s outer rim to a depth of roughly three centimeters. The six patients in the series who received ICG-based marking had a median procedure time of 16.5 minutes.

The most innovative variant described in the report goes one step further: instead of injecting liquid dye that will eventually disperse, the team deploys a tiny embolization coil soaked in ICG. The preparation is meticulous. ICG is mixed with ten milliliters of sterile water, and two to three milliliters of the solution are used to slowly flush the coil introducer outside the patient to prevent premature deployment. The markers are Tornado-type coils measuring 0.035 inches in diameter and 7 to 8 millimeters in length. After percutaneous puncture with an 18-gauge coaxial needle, the coil is advanced with the stiff end of a guidewire and deployed under CT-fluoroscopy immediately adjacent to the lesion, with care taken not to push it too far past the target. The coil acts as a physical scaffold that holds the dye in place, and because the fluorescence persists for days, surgery can be scheduled up to thirteen days after marking, giving hospitals valuable flexibility when operating rooms are crowded or schedules shift unexpectedly.

Safety data from the series align with the broader literature. Only one complication occurred, an asymptomatic pneumothorax during needle puncture that was managed conservatively without any intervention, consistent with reported pneumothorax rates of around six percent for CT-guided ICG injection in a retrospective analysis of 471 patients. The authors do caution that coil placement requires a larger 18-gauge needle than pure dye injection, which may influence complication rates. Prior studies have reported technical success rates above 98 percent for CT-guided dye injection and 100 percent for bronchoscopy-guided ICG-coil placement, and the addition of preoperative markings has been shown in other reports to drive conversion rates to open surgery close to zero.

What makes the Berlin report notable is the delivery route. ICG-soaked coil marking had previously been described through bronchoscopy, a technique that requires general anesthesia and specialized endoscopic equipment, and only recently through a percutaneous approach. The CT-guided percutaneous route can be performed in an outpatient workflow under local anesthesia alone, making it less resource-intensive and easier to slot into a busy hospital schedule. The authors emphasize that the technique is ultimately a story about multidisciplinary collaboration: the tumor board decides the patient needs lung-sparing surgery, the interventional radiologist plants the beacon, and the thoracic surgeon follows the glow. As robotic-assisted and uniportal thoracoscopic surgery become more common and screening programs continue to surface ever-smaller nodules, dye-based marking may become a routine bridge between the radiology suite and the operating room, turning invisible targets into ones a surgeon cannot miss.

Subject of Research: CT-guided preoperative dye-based marking of small lung nodules for minimally invasive surgical resection

Article Title: CT-guided percutaneous marking of lung nodules using patent blue V and indocyanine green

Article References: Hamm, C. A., Elsner, A., Fehrenbach, U., Savic, L. J., Bawaadam, H., Collettini, F., Neudecker, J., Gebauer, B., Rückert, J., & Auer, T. A. (2026). CT-guided percutaneous marking of lung nodules using patent blue V and indocyanine green. CVIR Oncology, 2(1), Article 2. https://doi.org/10.1007/s44343-026-00031-9

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00031-9

Keywords: lung nodules, interventional radiology, indocyanine green, patent blue V, CT guidance, thoracic surgery, fluorescence imaging, preoperative localization, lung cancer screening, video-assisted thoracoscopic surgery, fiducial coils, lung-sparing resection